HRP20201175T1 - Derivati 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ona i njihova upotreba kao dvostrukih inhibitora fosfatidilinozitola 3-kinaze delta i gama - Google Patents

Derivati 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ona i njihova upotreba kao dvostrukih inhibitora fosfatidilinozitola 3-kinaze delta i gama Download PDF

Info

Publication number
HRP20201175T1
HRP20201175T1 HRP20201175TT HRP20201175T HRP20201175T1 HR P20201175 T1 HRP20201175 T1 HR P20201175T1 HR P20201175T T HRP20201175T T HR P20201175TT HR P20201175 T HRP20201175 T HR P20201175T HR P20201175 T1 HRP20201175 T1 HR P20201175T1
Authority
HR
Croatia
Prior art keywords
methyl
pyridin
dihydro
thiazol
amino
Prior art date
Application number
HRP20201175TT
Other languages
English (en)
Croatian (hr)
Inventor
Matthew Perry
Konstantinos Karabelas
Mickael Mogemark
Peter Bold
Christian Tyrchan
Antonios Nikitidis
Jens Petersen
Ulf BÖRJESSON
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20201175T1 publication Critical patent/HRP20201175T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20201175TT 2016-09-22 2017-09-21 Derivati 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ona i njihova upotreba kao dvostrukih inhibitora fosfatidilinozitola 3-kinaze delta i gama HRP20201175T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398006P 2016-09-22 2016-09-22
PCT/EP2017/073916 WO2018055040A1 (en) 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma
EP17772381.4A EP3515910B1 (en) 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma

Publications (1)

Publication Number Publication Date
HRP20201175T1 true HRP20201175T1 (hr) 2020-11-13

Family

ID=59966739

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201175TT HRP20201175T1 (hr) 2016-09-22 2017-09-21 Derivati 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ona i njihova upotreba kao dvostrukih inhibitora fosfatidilinozitola 3-kinaze delta i gama

Country Status (36)

Country Link
US (2) US10961236B2 (enExample)
EP (1) EP3515910B1 (enExample)
JP (1) JP6765516B2 (enExample)
KR (1) KR102226098B1 (enExample)
CN (1) CN109715623A (enExample)
AR (1) AR109706A1 (enExample)
AU (1) AU2017331940B2 (enExample)
BR (1) BR112019004719A2 (enExample)
CA (1) CA3036304A1 (enExample)
CL (1) CL2019000707A1 (enExample)
CO (1) CO2019003440A2 (enExample)
CR (1) CR20190200A (enExample)
CY (1) CY1123346T1 (enExample)
DK (1) DK3515910T3 (enExample)
DO (1) DOP2019000073A (enExample)
EA (1) EA036176B1 (enExample)
EC (1) ECSP19027780A (enExample)
ES (1) ES2818583T3 (enExample)
HR (1) HRP20201175T1 (enExample)
HU (1) HUE051634T2 (enExample)
IL (1) IL265298B (enExample)
JO (1) JOP20190052A1 (enExample)
LT (1) LT3515910T (enExample)
MA (1) MA46268B1 (enExample)
MX (2) MX381898B (enExample)
PE (1) PE20190909A1 (enExample)
PH (1) PH12019500615A1 (enExample)
PL (1) PL3515910T3 (enExample)
PT (1) PT3515910T (enExample)
RS (1) RS60764B1 (enExample)
SI (1) SI3515910T1 (enExample)
SM (1) SMT202000481T1 (enExample)
SV (1) SV2019005857A (enExample)
TW (1) TW201813967A (enExample)
UA (1) UA123558C2 (enExample)
WO (1) WO2018055040A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
CN115677692A (zh) * 2019-04-10 2023-02-03 南京征祥医药有限公司 磷脂酰肌醇3-激酶抑制剂
JP7665534B2 (ja) 2019-06-04 2025-04-21 アーカス バイオサイエンシーズ インコーポレイテッド 2,3,5-三置換ピラゾロ[1,5-a]ピリミジン化合物
CN114258393B (zh) * 2020-07-21 2024-11-22 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2022023456A1 (en) 2020-07-29 2022-02-03 Astrazeneca Ab Pharmaceutical compositions comprising nano embedded microparticles and methods of use
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257461T3 (es) * 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
CA2610884A1 (en) * 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
JP5561702B2 (ja) * 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Pi3キナーゼ調節剤および使用方法
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環式化合物及びその使用
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
CA2850763A1 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
JP6371838B2 (ja) 2013-07-02 2018-08-08 ライゼン・ファーマシューティカルズ・エスアー Pi3kタンパク質キナーゼ阻害剤、特に、デルタ及び/またはガンマ阻害剤
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
EA031135B1 (ru) 2014-06-27 2018-11-30 Ризен Фармасьютикалз Са Замещенные производные хромена как селективные двойные ингибиторы протеинкиназ pi3 дельта и гамма

Also Published As

Publication number Publication date
MX381898B (es) 2025-03-13
EP3515910B1 (en) 2020-07-15
PT3515910T (pt) 2020-09-16
WO2018055040A1 (en) 2018-03-29
US20200308164A1 (en) 2020-10-01
BR112019004719A2 (pt) 2019-05-28
CA3036304A1 (en) 2018-03-29
ES2818583T3 (es) 2021-04-13
EA036176B1 (ru) 2020-10-09
DOP2019000073A (es) 2019-04-15
JP6765516B2 (ja) 2020-10-07
CY1123346T1 (el) 2022-03-24
KR20190049867A (ko) 2019-05-09
MA46268A (fr) 2019-07-31
PE20190909A1 (es) 2019-06-26
MX2021004748A (es) 2021-06-08
MX2019003194A (es) 2019-06-17
PH12019500615A1 (en) 2019-06-03
JOP20190052A1 (ar) 2019-03-21
US20210246130A1 (en) 2021-08-12
AR109706A1 (es) 2019-01-16
CR20190200A (es) 2019-06-07
LT3515910T (lt) 2020-10-12
EA201990664A1 (ru) 2019-08-30
UA123558C2 (uk) 2021-04-21
ECSP19027780A (es) 2019-04-30
MA46268B1 (fr) 2020-08-31
TW201813967A (zh) 2018-04-16
EP3515910A1 (en) 2019-07-31
HUE051634T2 (hu) 2021-03-01
JP2019529445A (ja) 2019-10-17
KR102226098B1 (ko) 2021-03-09
AU2017331940A1 (en) 2019-05-02
AU2017331940B2 (en) 2020-03-12
SMT202000481T1 (it) 2020-11-10
IL265298A (en) 2019-05-30
US10961236B2 (en) 2021-03-30
CO2019003440A2 (es) 2019-04-12
CL2019000707A1 (es) 2019-05-31
SI3515910T1 (sl) 2020-09-30
DK3515910T3 (da) 2020-08-31
CN109715623A (zh) 2019-05-03
IL265298B (en) 2020-09-30
RS60764B1 (sr) 2020-10-30
SV2019005857A (es) 2019-05-06
PL3515910T3 (pl) 2021-02-22

Similar Documents

Publication Publication Date Title
HRP20201175T1 (hr) Derivati 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ona i njihova upotreba kao dvostrukih inhibitora fosfatidilinozitola 3-kinaze delta i gama
JP2019529445A5 (enExample)
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
HRP20170352T1 (hr) Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori
RU2018138707A (ru) Замещенные гетероарилом пиридины и способы применения
HRP20160635T1 (hr) Inhibitori pirimidina pde10
JP2013545744A5 (enExample)
JP2011503230A5 (enExample)
HRP20211960T1 (hr) Alosterični modulatori nikotinskih acetilcolinskih receptora
JP2020527560A5 (enExample)
JP2014525432A5 (enExample)
JP2018507234A5 (enExample)
HRP20161797T1 (hr) Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina
JP2009524670A5 (enExample)
RU2018112237A (ru) Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
HRP20192323T1 (hr) Novi derivati dihidrokinolin-2-ona
AR078731A1 (es) Octahidropirrolo (3,4-c) pirroles disustituidos como moduladores del receptor de orexina
JP2009529059A5 (enExample)
JP2012511588A5 (enExample)
JP2018536671A5 (enExample)
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
HRP20181017T1 (hr) Heterociklični spojevi i postupci uporabe
JP2018515525A5 (enExample)
JP2014528450A5 (enExample)